<DOC>
	<DOC>NCT00717925</DOC>
	<brief_summary>To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).</brief_summary>
	<brief_title>Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>CD22positive, Bcell NHL which has progressed after 1 or 2 prior therapies. Patients who have progressed after at least 1 prior chemotherapy regimen for indolent lymphoma, or 1/ 2 chemotherapy regimens, which include anthracylin or anthraquinon for aggressive lymphoma. Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1. Patients must not have received monoclonal antibodies or radioimmunoconjugates within 3 months before first dose of test article. Patients must not have received bilateral pelvic irradiation. Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 4 weeks before first dose of test article.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>B-cell Non-Hodgkin's Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>